Cargando…

Pilot Study of Real-World Monitoring of the Heart Rate Variability in Amyotrophic Lateral Sclerosis

AIMS: Cardiovascular dysautonomia may impact the quality of life and survival in amyotrophic lateral sclerosis (ALS). Such dysfunction is not systematically assessed in these patients. Wearable devices could help. The feasibility of a wearable biosensor to detect heart rate variability (HRV), a phys...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, Alexander A., Ferguson, Bradley J., Jones, Vovanti, Green, Bruce E., Pearre, Justin D., Anunoby, Ifeoma A., Beversdorf, David Q., Barohn, Richard J., Cirstea, Carmen M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9301244/
https://www.ncbi.nlm.nih.gov/pubmed/35875194
http://dx.doi.org/10.3389/frai.2022.910049
_version_ 1784751386636845056
author Brown, Alexander A.
Ferguson, Bradley J.
Jones, Vovanti
Green, Bruce E.
Pearre, Justin D.
Anunoby, Ifeoma A.
Beversdorf, David Q.
Barohn, Richard J.
Cirstea, Carmen M.
author_facet Brown, Alexander A.
Ferguson, Bradley J.
Jones, Vovanti
Green, Bruce E.
Pearre, Justin D.
Anunoby, Ifeoma A.
Beversdorf, David Q.
Barohn, Richard J.
Cirstea, Carmen M.
author_sort Brown, Alexander A.
collection PubMed
description AIMS: Cardiovascular dysautonomia may impact the quality of life and survival in amyotrophic lateral sclerosis (ALS). Such dysfunction is not systematically assessed in these patients. Wearable devices could help. The feasibility of a wearable biosensor to detect heart rate variability (HRV), a physiological marker of sympathovagal balance, was studied for the first time in real-world settings in ALS. METHODS: Five ALS patients (two early/three late; one bulbar-onset; mildly-to-moderately disabled) and five age/sex/BMI/comorbidities-matched controls underwent assessment of 3-day HRV via VitalConnect biosensor (worn on the left thorax). De-identified data captured by the biosensor were transferred to a secure cloud server via a relay Bluetooth device. Baseline ALS severity/anxiety and physical activity during testing were documented/quantified. Time-domain HRV measures (i.e., pNN50) were analyzed. RESULTS: An overall 3-day abnormal HRV (pNN50 < 3%), was found in three out of five patients (mean ± SD for the group, 2.49 ± 1.51). Similar changes were reported in controls (12.32 ± 21.14%). There were no statistically significant relationships between pNN50 values and baseline anxiety or physical activity during the tested days (p > 0.05 for both groups). A negative correlation was found between pNN50 values and age in patients (p = 0.01) and controls (p = 0.09), which is similar with what is found in the general population. In line with prior studies, pNN50 values were independent of disease stage (p = 0.6) and disability (p = 0.4). CONCLUSIONS: These preliminary results suggest that remote HRV measures using the VitalConnect is feasible and may constitute an improved strategy to provide insights into sympathovagal balance in ALS. Further work with larger sample sizes is warranted.
format Online
Article
Text
id pubmed-9301244
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93012442022-07-22 Pilot Study of Real-World Monitoring of the Heart Rate Variability in Amyotrophic Lateral Sclerosis Brown, Alexander A. Ferguson, Bradley J. Jones, Vovanti Green, Bruce E. Pearre, Justin D. Anunoby, Ifeoma A. Beversdorf, David Q. Barohn, Richard J. Cirstea, Carmen M. Front Artif Intell Artificial Intelligence AIMS: Cardiovascular dysautonomia may impact the quality of life and survival in amyotrophic lateral sclerosis (ALS). Such dysfunction is not systematically assessed in these patients. Wearable devices could help. The feasibility of a wearable biosensor to detect heart rate variability (HRV), a physiological marker of sympathovagal balance, was studied for the first time in real-world settings in ALS. METHODS: Five ALS patients (two early/three late; one bulbar-onset; mildly-to-moderately disabled) and five age/sex/BMI/comorbidities-matched controls underwent assessment of 3-day HRV via VitalConnect biosensor (worn on the left thorax). De-identified data captured by the biosensor were transferred to a secure cloud server via a relay Bluetooth device. Baseline ALS severity/anxiety and physical activity during testing were documented/quantified. Time-domain HRV measures (i.e., pNN50) were analyzed. RESULTS: An overall 3-day abnormal HRV (pNN50 < 3%), was found in three out of five patients (mean ± SD for the group, 2.49 ± 1.51). Similar changes were reported in controls (12.32 ± 21.14%). There were no statistically significant relationships between pNN50 values and baseline anxiety or physical activity during the tested days (p > 0.05 for both groups). A negative correlation was found between pNN50 values and age in patients (p = 0.01) and controls (p = 0.09), which is similar with what is found in the general population. In line with prior studies, pNN50 values were independent of disease stage (p = 0.6) and disability (p = 0.4). CONCLUSIONS: These preliminary results suggest that remote HRV measures using the VitalConnect is feasible and may constitute an improved strategy to provide insights into sympathovagal balance in ALS. Further work with larger sample sizes is warranted. Frontiers Media S.A. 2022-07-07 /pmc/articles/PMC9301244/ /pubmed/35875194 http://dx.doi.org/10.3389/frai.2022.910049 Text en Copyright © 2022 Brown, Ferguson, Jones, Green, Pearre, Anunoby, Beversdorf, Barohn and Cirstea. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Artificial Intelligence
Brown, Alexander A.
Ferguson, Bradley J.
Jones, Vovanti
Green, Bruce E.
Pearre, Justin D.
Anunoby, Ifeoma A.
Beversdorf, David Q.
Barohn, Richard J.
Cirstea, Carmen M.
Pilot Study of Real-World Monitoring of the Heart Rate Variability in Amyotrophic Lateral Sclerosis
title Pilot Study of Real-World Monitoring of the Heart Rate Variability in Amyotrophic Lateral Sclerosis
title_full Pilot Study of Real-World Monitoring of the Heart Rate Variability in Amyotrophic Lateral Sclerosis
title_fullStr Pilot Study of Real-World Monitoring of the Heart Rate Variability in Amyotrophic Lateral Sclerosis
title_full_unstemmed Pilot Study of Real-World Monitoring of the Heart Rate Variability in Amyotrophic Lateral Sclerosis
title_short Pilot Study of Real-World Monitoring of the Heart Rate Variability in Amyotrophic Lateral Sclerosis
title_sort pilot study of real-world monitoring of the heart rate variability in amyotrophic lateral sclerosis
topic Artificial Intelligence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9301244/
https://www.ncbi.nlm.nih.gov/pubmed/35875194
http://dx.doi.org/10.3389/frai.2022.910049
work_keys_str_mv AT brownalexandera pilotstudyofrealworldmonitoringoftheheartratevariabilityinamyotrophiclateralsclerosis
AT fergusonbradleyj pilotstudyofrealworldmonitoringoftheheartratevariabilityinamyotrophiclateralsclerosis
AT jonesvovanti pilotstudyofrealworldmonitoringoftheheartratevariabilityinamyotrophiclateralsclerosis
AT greenbrucee pilotstudyofrealworldmonitoringoftheheartratevariabilityinamyotrophiclateralsclerosis
AT pearrejustind pilotstudyofrealworldmonitoringoftheheartratevariabilityinamyotrophiclateralsclerosis
AT anunobyifeomaa pilotstudyofrealworldmonitoringoftheheartratevariabilityinamyotrophiclateralsclerosis
AT beversdorfdavidq pilotstudyofrealworldmonitoringoftheheartratevariabilityinamyotrophiclateralsclerosis
AT barohnrichardj pilotstudyofrealworldmonitoringoftheheartratevariabilityinamyotrophiclateralsclerosis
AT cirsteacarmenm pilotstudyofrealworldmonitoringoftheheartratevariabilityinamyotrophiclateralsclerosis